A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
NCT ID: NCT04634409
Last Updated: 2022-07-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
1755 participants
INTERVENTIONAL
2020-10-29
2021-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
NCT04691180
Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196
NCT04479631
A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19
NCT04822701
A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
NCT04787211
A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19
NCT04770467
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo (Pbo)
Treatment 1: Pbo administered intravenously (IV).
Treatment 8: Pbo For 700 mg Bamlanivimab (BAM) + 500 mg VIR-7831 (Amendment (C-e)) administered IV.
Treatment 11: Pbo For 175 mg Bebtelovimab (BEB) \& 700 mg BAM +1400 mg Etesevimab ( ETE) +175 mg BEB (Low Risk Participants) administered IV.
Pooled Placebo (Addendum 4, IV) administered IV.
Pooled Placebo (Addendum 4, SC) administered SC.
Placebo
Administered IV.
BAM + ETE
Treatment 2: 175 mg BAM +350 mg ETE administered IV.
Treatment 3: 700 mg BAM +1400 mg ETE administered IV.
Treatment 4: 2800 mg BAM +2800 mg ETE administered IV.
Treatment 6: 350 mg BAM +700 mg ETE administered IV.
Unintentional Dosing: 700 mg BAM +700 mg ETE administered IV.
700 mg BAM + 1400 mg ETE 30-min (Addendum (2)) administered IV.
700 mg BAM + 1400 mg ETE 15-min (Addendum (2)) administered IV.
Bamlanivimab
Administered IV.
Etesevimab
Administered IV.
BAM
Treatment 5: 700 mg BAM administered IV.
700 mg BAM 15-min (Addendum (2)) administered IV.
Bamlanivimab
Administered IV.
BAM + VIR-7831
Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e)) administered IV.
Bamlanivimab
Administered IV.
VIR-7831
Administered IV.
BEB
Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants) administered IV.
Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants) administered IV.
70 mg BEB 140 mg/Min (Addendum 4, IV) administered IV.
175 mg BEB 140 mg/Min (Addendum 4, IV) administered IV.
175 mg BEB 350 mg/Min (Addendum 4, IV) administered IV.
1750 mg BEB 350 mg/Min (Addendum 4, IV) administered IV.
280 mg BEB (Addendum 4, SC) administered SC.
560 mg BEB (Addendum 4, SC) administered SC.
Bebtelovimab
Administered IV.
BAM+ ETE + BEB
Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants) administered IV.
Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants) administered IV.
Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk, Updated Centers for Disease Control and Prevention (CDC) Criteria) administered IV.
175/700/1400 mg BAM + ETE + BEB 350 mg/Min (Addendum 4, IV) administered IV.
Bamlanivimab
Administered IV.
Etesevimab
Administered IV.
Bebtelovimab
Administered IV.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bamlanivimab
Administered IV.
Etesevimab
Administered IV.
Placebo
Administered IV.
VIR-7831
Administered IV.
Bebtelovimab
Administered IV.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For high-risk participant arms 12 and 13 only:
\-- Are ≥18 years of age and satisfy at least one of the following risk factors at the time of screening
* Are ≥65 years of age
* Have a body mass index (BMI) ≥ 35
* Have chronic kidney disease
* Have type 1 or type 2 diabetes
* Have immunosuppressive disease
* Are currently receiving immunosuppressive treatment, or
* Are ≥55 years of age AND have
* cardiovascular disease, OR
* hypertension, OR
* chronic obstructive pulmonary disease or other chronic respiratory disease
* For high-risk participant arms 12 and 13 only:
* Are 12-17 years of age (inclusive) AND satisfy at least one of the following risk factors at the time of screening
* Have a BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical\_charts.htm
* Have sickle cell disease
* Have congenital or acquired heart disease
* Have neurodevelopmental disorders, for example, cerebral palsy
* Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)
* Have asthma or reactive airway or other chronic respiratory disease that requires daily medication for control
* Have type 1 or type 2 diabetes
* Have chronic kidney disease
* Have immunosuppressive disease, or
* Are currently receiving immunosuppressive treatment.
For high-risk participants arm 14 only:
* Are ≥12 years of age and satisfy at least one of the following risk factors at the time of screening Are ≥65 years of age
* Are adults (≥18 years of age) with BMI \>25 kg/m2 , or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts
* Have chronic kidney disease
* Have type 1 or type 2 diabetes
* Have immunosuppressive disease
* Are currently receiving immunosuppressive treatment
* Have cardiovascular disease (including congenital heart disease) or hypertension
* Have chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma \[moderate-to-severe\], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
* Have sickle cell disease
* Have neurodevelopmental disorder (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
* Have a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation \[not related to COVID-19\]
* Are currently not hospitalized
* Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion, nasal congestion or runny nose, new loss of smell, chills
* Must have sample taken for test confirming viral infection no more than 3 days prior to starting the drug infusion
* Are men or non-pregnant women who agree to contraceptive requirements
* Understand and agree to comply with planned study procedures
* Agree to the collection of nasopharyngeal swabs and venous blood
* The participant or legally authorized representative give signed informed consent and/or assent
Exclusion Criteria
* Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to fractional inspired oxygen (FiO2) \<300, respiratory rate ≥30 per minute, heart rate ≥125 per minute
* Require mechanical ventilation or anticipated impending need for mechanical ventilation
* Have known allergies to any of the components used in the formulation of the interventions
* Have hemodynamic instability requiring use of pressors within 24 hours of randomization
* Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention
* Have any co-morbidity requiring surgery within \<7 days, or that is considered life-threatening within 29 days
* Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study
* Have a history of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test prior to the one serving as eligibility for this study
* Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing
* Have received treatment with a SARS-CoV-2 specific monoclonal antibody
* Have a history of convalescent COVID-19 plasma treatment
* For low-risk arms only: have received a SARS-CoV-2 vaccine or have participated in a previous SARS-CoV-2 vaccine study and are currently blinded to treatment allotment
* Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed
* Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
* Are pregnant or breast feeding
* Are investigator site personnel directly affiliated with this study
* Have body weight \<40 kilograms
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbCellera Biologics Inc.
INDUSTRY
Shanghai Junshi Bioscience Co., Ltd.
OTHER
GlaxoSmithKline
INDUSTRY
Vir Biotechnology, Inc.
INDUSTRY
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
The Institute for Liver Health
Mesa, Arizona, United States
Perseverance Research Center
Scottsdale, Arizona, United States
CRI of Arizona, LLC
Sun City West, Arizona, United States
Fiel Family and Sports Medicine PC
Tempe, Arizona, United States
The Institute for Liver Health
Tucson, Arizona, United States
KLR Business Group, Inc. dba Arkansas Clinical Research
Little Rock, Arkansas, United States
Applied Rsch Ctr - Arkansas Inc.
Little Rock, Arkansas, United States
Smart Cures Clin Research
Anaheim, California, United States
Hope Clinical Research
Canoga Park, California, United States
VCT-Covina
Covina, California, United States
Neighborhood Healthcare
Escondido, California, United States
Chemidox Clinical Trials
Lancaster, California, United States
Ark Clinical Research
Long Beach, California, United States
Long Beach Clinical Trials LLC
Long Beach, California, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Central Valley Research, LLC
Modesto, California, United States
Inland Empire Liver Foundation
Rialto, California, United States
Sutter Institute For Medical Research
Sacramento, California, United States
Wolverine Clinical Trials, LLC
Santa Ana, California, United States
St. Joe Heritage HC-Santa Rosa
Santa Rosa, California, United States
Stanford University Hospital
Stanford, California, United States
Mazur, Statner, Dutta, Nathan
Thousand Oaks, California, United States
South Bay Clinical Research Institute
Torrance, California, United States
Infect Disease Doctors Med Grp
Walnut Creek, California, United States
Allianz Research Institute
Westminster, California, United States
Future Innovative Treatments LLC
Colorado Springs, Colorado, United States
Georgetown Univ Sch of Med
Washington D.C., District of Columbia, United States
Synergy Healthcare LLC
Bradenton, Florida, United States
Holy Cross Hospital Inc.
Fort Lauderdale, Florida, United States
I R & Health Center, Inc.
Hialeah, Florida, United States
Encore Medical Research
Hollywood, Florida, United States
Elixia CRC
Hollywood, Florida, United States
Lakeland Regional Medical Center
Lakeland, Florida, United States
Hope Clinical Trials, Inc.
Miami, Florida, United States
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, United States
Bio-Medical Research, LLC
Miami, Florida, United States
Clinical Site Partners, LLC d/b/a CSP Miami
Miami, Florida, United States
Panax Clinical Research
Miami Lakes, Florida, United States
Testing Matters Lab
Sunrise, Florida, United States
Advent Health Tampa
Tampa, Florida, United States
Triple O Research Inst
West Palm Beach, Florida, United States
Encore Medical Research - Weston
Weston, Florida, United States
Clinical Site Partners, LLC DBA CSP Orlando
Winter Park, Florida, United States
Gwinnett Research Inst
Buford, Georgia, United States
Paramount Rch Sol - College Pk
College Park, Georgia, United States
IACT Health - VHC
Columbus, Georgia, United States
Central Georgia Infectious Disease
Macon, Georgia, United States
Rophe Adult and Pediatric Medicine
Union City, Georgia, United States
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Great Lakes Clinical Trials
Chicago, Illinois, United States
Franciscan Health Hammond
Dyer, Indiana, United States
Qualmedica Research Evansville
Evansville, Indiana, United States
Franciscan St. Francis Health
Indianapolis, Indiana, United States
St.Vincent - Indy
Indianapolis, Indiana, United States
Qualmedica Research, LLC
Owensboro, Kentucky, United States
Tandem Clinical Research,LLC
Marrero, Louisiana, United States
Imperial Health Urgent Care Center - Moss Bluff
Moss Bluff, Louisiana, United States
Nola Research Works, LLC
New Orleans, Louisiana, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
U of MA Mem Med Ctr
Worcester, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
Revive Research Institute
Farmington Hills, Michigan, United States
Revival Research Institute
Sterling Heights, Michigan, United States
Sky Clinical Prime and Health Wellness Clinic
Fayette, Mississippi, United States
Olive Branch Family Medical Center
Olive Branch, Mississippi, United States
Sky Clin Resch - Quinn HC
Ridgeland, Mississippi, United States
Bio-Kinetic Clinical Applications, LLC
Springfield, Missouri, United States
Quality Clinical Research
Omaha, Nebraska, United States
Excel Clinical Research
Las Vegas, Nevada, United States
Las Vegas Medical Research
Las Vegas, Nevada, United States
SVG Clinical
Las Vegas, Nevada, United States
Holy Name Medical Center
Teaneck, New Jersey, United States
Prime Global Research, LLC
The Bronx, New York, United States
Onsite Clinical Solutions, LLC
Charlotte, North Carolina, United States
East Carolina University
Greenville, North Carolina, United States
Monroe Biomed Research
Monroe, North Carolina, United States
Carteret Medical Group
Morehead City, North Carolina, United States
PMG Research of Wilmington
Wilmington, North Carolina, United States
Valley Medical Primary Care
Centerville, Ohio, United States
Hometown UC and Rch- Cincy
Cincinnati, Ohio, United States
Aventiv Research Inc
Columbus, Ohio, United States
Urgent Care Specialists, LLC
Columbus, Ohio, United States
Remington-Davis, Inc
Columbus, Ohio, United States
Urgent Care Specialists, LLC
Dayton, Ohio, United States
META Medical Research Institute
Dayton, Ohio, United States
Ascension St. John Tulsa OK
Tulsa, Oklahoma, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Jefferson Hosp for Neurosci
Philadelphia, Pennsylvania, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
VITALINK - Anderson
Anderson, South Carolina, United States
Carolina Medical Research - Clinton
Clinton, South Carolina, United States
VITALINK - Gaffney
Gaffney, South Carolina, United States
Carolina Medical Research - Greenville
Greenville, South Carolina, United States
VITALINK - Greenville
Greenville, South Carolina, United States
VITALINK - Spartanburg
Spartanburg, South Carolina, United States
VITALINK - Union
Union, South Carolina, United States
Univ Diab & Endo Consult
Chattanooga, Tennessee, United States
New Phase Research and Development
Knoxville, Tennessee, United States
Gadolin Research, LLC
Beaumont, Texas, United States
Conroe Willis Medical Research
Conroe, Texas, United States
Crossroads Clinical Research
Corpus Christi, Texas, United States
B S & W Med Center
Dallas, Texas, United States
Baylor - Fort Worth
Fort Worth, Texas, United States
North Texas Clinical Trials, LLC
Fort Worth, Texas, United States
Houston Methodist Research Ins
Houston, Texas, United States
Next Level Urgent Care
Houston, Texas, United States
Accurate Clinical Management, LLC.
Houston, Texas, United States
1960 Family Practice, PA
Houston, Texas, United States
B S & W Med Center
Irving, Texas, United States
Zion Urgent Care Clinic
Katy, Texas, United States
BioPharma Family Practice Center McAllen
McAllen, Texas, United States
BRCR Medical Center, Inc
McAllen, Texas, United States
North Hills Medical Research
North Richland Hills, Texas, United States
Bay Area Infectious Diseases Associates
Pasadena, Texas, United States
Epic Medical Research
Red Oak, Texas, United States
Baylor - Round Rock
Round Rock, Texas, United States
Sun Research Institute
San Antonio, Texas, United States
Consano Clinical Research, LLC
Shavano Park, Texas, United States
APD Clinical Research
Splendora, Texas, United States
Crossroads Clin Rch-Victoria
Victoria, Texas, United States
CLS Research Ctr, PLLC
Webster, Texas, United States
CARE ID
Annandale, Virginia, United States
Evergreen Health Research
Kirkland, Washington, United States
Sanatorio Sagrado Corazón
Ciudad de Buenos Aires, AR, Argentina
Clínica Zabala
Ciudad de Buenos Aires, AR, Argentina
Sanatorio de la Trinidad Mitre
CABA, Buenos Aires, Argentina
Clínica Privada Independencia
Munro, Buenos Aires, Argentina
Go Centro Medico San Nicolás
San Nicolás de los Arroyos, Buenos Aires, Argentina
Instituto de Investigaciones Clinicas Zarate
Zárate, Buenos Aires, Argentina
Instituto Médico Rio Cuarto
Río Cuarto, Córdoba Province, Argentina
Centro de Investigaciones Clínicas - Clínica Viedma
Viedma, Río Negro Province, Argentina
Clinica Central S.A.
Villa Regina, Río Negro Province, Argentina
INECO Neurociencias Oroño
Rosario, Santa Fe Province, Argentina
Hospital San Roque
Córdoba, , Argentina
Advanced Clinical Research, LLC
Bayamón, , Puerto Rico
Dorado Medical Complex Inc
Dorado, , Puerto Rico
GCM Medical Group, PSC - Hato Rey Site
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nichols RM, Macpherson L, Patel DR, Yeh WW, Peppercorn A. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial. Infect Dis Ther. 2024 Feb;13(2):401-411. doi: 10.1007/s40121-024-00918-1. Epub 2024 Jan 30.
Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, Salomon S, Wood EM, So-Osman C, McQuilten Z, Spinner CD, Malin JJ, Stegemann M, Skoetz N, Kreuzberger N. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
Nathan R, Shawa I, De La Torre I, Pustizzi JM, Haustrup N, Patel DR, Huhn G. A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2. Infect Dis Ther. 2021 Dec;10(4):1933-1947. doi: 10.1007/s40121-021-00515-6. Epub 2021 Aug 10.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol: Protocol: J2X-MC-PYAH
Document Type: Study Protocol: Protocol Addendum 2: J2X-MC-PYAH
Document Type: Study Protocol: Protocol Addendum 4: J2X-MC-PYAH
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J2X-MC-PYAH
Identifier Type: OTHER
Identifier Source: secondary_id
18160
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.